Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Greenfire Resources Ltd.’s GFR share price has dipped by 5.70%, which has investors questioning if this is right time to buy.

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

The following is a summary of “Associations between intercurrent events and cardiorenal clinical outcomes in non-diabetic ...

Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ...

For 40 patients who received the low-dose 0.03% LUT014 formulation, the treatment success rate was also higher (47.5%) than that with ... or delay of EGFR-targeted therapies.

AstraZeneca Partners with Revna Biosciences to Enhance Epidermal Growth Factor Receptor (EGFR) Biomarker Testing in Ghana ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.